[mmunotherapy of cutaneous melanoma - update 2022].

Melanoma treatment has been revolutionized during the last decade. Currently first line therapeutic options for advanced melanoma include immunotherapy with anti-PD-1 antibodies (combination of PD-1 and CTLA-4 blockers should be an option in a selected group of patients) or targeted therapy with BRAF and MEK inhibitors in BRAF V600 mutated tumors. This review aims to summarize long-term survival data of immunotherapy in cutaneous melanoma and to show possible directions of development in combined oncological modalities.